Quick Dispatch:
Your surmount-1 trial tirzepatide obesity without diabetes SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 trial tirzepatide obesity without diabetes SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes ships.
Need Help?
Questions about surmount-1 trial tirzepatide obesity without diabetes SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 trial tirzepatide obesity without diabetes SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes in your area.
💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers
28.50
How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast
29.15
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
22.75
Tirzepatide vs semaglutide: A new battle in obesity treatment
20.88
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
25.41
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
28.12
Full article: Tirzepatide for overweight and obesity management
25.10
:max_bytes(150000):strip_icc()/VWH-Zepbound-a91ec7a305e8407d83daa7b41039b4aa.jpg)
